300 related articles for article (PubMed ID: 22743037)
61. Modeling HIV persistence, the latent reservoir, and viral blips.
Rong L; Perelson AS
J Theor Biol; 2009 Sep; 260(2):308-31. PubMed ID: 19539630
[TBL] [Abstract][Full Text] [Related]
62. A broad drug arsenal to attack a strenuous latent HIV reservoir.
Stoszko M; Ne E; Abner E; Mahmoudi T
Curr Opin Virol; 2019 Oct; 38():37-53. PubMed ID: 31323521
[TBL] [Abstract][Full Text] [Related]
63. Treating primary HIV infection--is your HAART in it?
Smith DE; Chan DJ
Sex Health; 2004; 1(3):131-5. PubMed ID: 16335299
[No Abstract] [Full Text] [Related]
64. SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques.
Dashti A; Waller C; Mavigner M; Schoof N; Bar KJ; Shaw GM; Vanderford TH; Liang S; Lifson JD; Dunham RM; Ferrari G; Tuyishime M; Lam CK; Nordstrom JL; Margolis DM; Silvestri G; Chahroudi A
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817214
[TBL] [Abstract][Full Text] [Related]
65. Regulation of human immunodeficiency virus-1 latency and its reactivation.
Verdin E
Bull Mem Acad R Med Belg; 2008; 163(6):355-64; discussion 364-5. PubMed ID: 19445107
[TBL] [Abstract][Full Text] [Related]
66. Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells.
Sung JA; Sholtis K; Kirchherr J; Kuruc JD; Gay CL; Nordstrom JL; Bollard CM; Archin NM; Margolis DM
EBioMedicine; 2017 Sep; 23():52-58. PubMed ID: 28803740
[TBL] [Abstract][Full Text] [Related]
67. Establishment of a Novel Humanized Mouse Model To Investigate
Flerin NC; Bardhi A; Zheng JH; Korom M; Folkvord J; Kovacs C; Benko E; Truong R; Mota T; Connick E; Jones RB; Lynch RM; Goldstein H
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626677
[TBL] [Abstract][Full Text] [Related]
68. Differentiating Immune Cell Targets in Gut-Associated Lymphoid Tissue for HIV Cure.
Khan S; Telwatte S; Trapecar M; Yukl S; Sanjabi S
AIDS Res Hum Retroviruses; 2017 Nov; 33(S1):S40-S58. PubMed ID: 28882067
[TBL] [Abstract][Full Text] [Related]
69. IP-10 Promotes Latent HIV Infection in Resting Memory CD4
Wang Z; Yin X; Ma M; Ge H; Lang B; Sun H; He S; Fu Y; Sun Y; Yu X; Zhang Z; Cui H; Han X; Xu J; Ding H; Chu Z; Shang H; Wu Y; Jiang Y
Front Immunol; 2021; 12():656663. PubMed ID: 34447368
[TBL] [Abstract][Full Text] [Related]
70. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy.
Blazkova J; Chun TW; Belay BW; Murray D; Justement JS; Funk EK; Nelson A; Hallahan CW; Moir S; Wender PA; Fauci AS
J Infect Dis; 2012 Sep; 206(5):765-9. PubMed ID: 22732922
[TBL] [Abstract][Full Text] [Related]
71. HIV reservoir dynamics in the face of highly active antiretroviral therapy.
Costiniuk CT; Jenabian MA
AIDS Patient Care STDS; 2015 Feb; 29(2):55-68. PubMed ID: 25412339
[TBL] [Abstract][Full Text] [Related]
72. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
Grau-Expósito J; Luque-Ballesteros L; Navarro J; Curran A; Burgos J; Ribera E; Torrella A; Planas B; Badía R; Martin-Castillo M; Fernández-Sojo J; Genescà M; Falcó V; Buzon MJ
PLoS Pathog; 2019 Aug; 15(8):e1007991. PubMed ID: 31425551
[TBL] [Abstract][Full Text] [Related]
73. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.
Chun TW; Stuyver L; Mizell SB; Ehler LA; Mican JA; Baseler M; Lloyd AL; Nowak MA; Fauci AS
Proc Natl Acad Sci U S A; 1997 Nov; 94(24):13193-7. PubMed ID: 9371822
[TBL] [Abstract][Full Text] [Related]
74. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.
Katlama C; Deeks SG; Autran B; Martinez-Picado J; van Lunzen J; Rouzioux C; Miller M; Vella S; Schmitz JE; Ahlers J; Richman DD; Sekaly RP
Lancet; 2013 Jun; 381(9883):2109-17. PubMed ID: 23541541
[TBL] [Abstract][Full Text] [Related]
75. Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy.
Sun H; Kim D; Li X; Kiselinova M; Ouyang Z; Vandekerckhove L; Shang H; Rosenberg ES; Yu XG; Lichterfeld M
J Virol; 2015 Nov; 89(22):11284-93. PubMed ID: 26339043
[TBL] [Abstract][Full Text] [Related]
76. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.
Chun TW; Justement JS; Moir S; Hallahan CW; Maenza J; Mullins JI; Collier AC; Corey L; Fauci AS
J Infect Dis; 2007 Jun; 195(12):1762-4. PubMed ID: 17492591
[TBL] [Abstract][Full Text] [Related]
77. Cytomegalovirus and HIV Persistence: Pouring Gas on the Fire.
Christensen-Quick A; Vanpouille C; Lisco A; Gianella S
AIDS Res Hum Retroviruses; 2017 Nov; 33(S1):S23-S30. PubMed ID: 29140108
[TBL] [Abstract][Full Text] [Related]
78. HIV latency.
Siliciano RF; Greene WC
Cold Spring Harb Perspect Med; 2011 Sep; 1(1):a007096. PubMed ID: 22229121
[TBL] [Abstract][Full Text] [Related]
79. Understanding Factors That Modulate the Establishment of HIV Latency in Resting CD4+ T-Cells In Vitro.
Anderson JL; Mota TM; Evans VA; Kumar N; Rezaei SD; Cheong K; Solomon A; Wightman F; Cameron PU; Lewin SR
PLoS One; 2016; 11(7):e0158778. PubMed ID: 27383184
[TBL] [Abstract][Full Text] [Related]
80. Progress and challenges in the use of latent HIV-1 reactivating agents.
Shang HT; Ding JW; Yu SY; Wu T; Zhang QL; Liang FJ
Acta Pharmacol Sin; 2015 Aug; 36(8):908-16. PubMed ID: 26027656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
